Entity

Time filter

Source Type

Danbury, CT, United States

IMS Health is a company that provides information, services and technology for the healthcare industry. It is the largest vendor of U.S. physician prescribing data. IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. Ari Bousbib is IMS Health’s Chairman and CEO. Bousbib, formerly a longtime senior executive at United Technologies Corporation, joined the company in September 2010. IMS Health is headquartered in Danbury, Connecticut. Wikipedia.


Huber K.,Cardiology and Emergency Medicine | Hamad B.,IMS Health
Nature Reviews Drug Discovery | Year: 2011

Ticagrelor (Brilique; AstraZeneca), an oral antiplatelet therapy, was granted marketing authorization by the European Commission in December 2010 for the prevention of atherothrombotic events in adult patients with acute coronary syndromes. © 2011 Macmillan Publishers Limited. All rights reserved. Source


Mesa R.A.,Mayo Medical School | Yasothan U.,IMS Health
Nature Reviews Drug Discovery | Year: 2012

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. © 2012 Macmillan Publishers Limited. All rights reserved. Source


Younes A.,University of Texas M. D. Anderson Cancer Center | Yasothan U.,IMS Health
Nature Reviews Drug Discovery | Year: 2012

In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibodyg-drug conjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with Hodgkin's lymphoma and patients with systemic anaplastic large cell lymphoma (ALCL). © 2012 Macmillan Publishers Limited. All rights reserved. Source


Vincenti F.,University of California at San Francisco | Dritselis A.,IMS Health
Nature Reviews Drug Discovery | Year: 2011

In June 2011, belatacept (Nulojix; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US Food and Drug Administration (FDA) for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. © 2011 Macmillan Publishers Limited. All rights reserved. Source


Stafstrom C.E.,University of Wisconsin - Madison | Grippon S.,IMS Health
Nature Reviews Drug Discovery | Year: 2011

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt). © 2011 Macmillan Publishers Limited. All rights reserved. Source

Discover hidden collaborations